HMP Global November 20, 2025
Adam Colborn, JD, associate vice president for congressional affairs at the Academy of Managed Care Pharmacy, discusses how the Trump administration’s “most favored nation” drug-pricing agreements test the limits of executive authority, signal potential long-term shifts in obesity treatment policy, and could drive broader market and regulatory realignments across both public and private payers.
Please introduce yourself by stating your name, title, and any relevant experience you’d like to share.
Adam Colborn, JD: I’m Adam Colborn. I am the associate vice president for congressional affairs at the Academy of Managed Care Pharmacy.
How does this new ‘most favored nation’ agreement fit within existing drug-pricing authorities? Do these deals rely on executive authority alone, or do they anticipate further legislative or...
Today's Sponsors
Today's Sponsor